The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
MISSISSAUGA, ON, June 23, 2025 /CNW/ - Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment ...
IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter ...
UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using ...
WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary ...
Ben McCullough was given a gift early in his tour of the Edwards Lifesciences headquarters on Wednesday morning. The lapel pin meant a lot to McCullough, as it represented the 56-millimeter EVOQUE ...
Just a smidge over 16 years ago, Edwards Lifesciences made heart valve history when it brought the first transcatheter aortic valve replacement (TAVR) system to market in Europe. Now, the TAVR pioneer ...
The company that pioneered the transcatheter aortic valve replacement (TAVR) market is leading the way again, this time in the transcatheter tricuspid valve replacement (TTVR) market. Edwards ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results